Report cover image

Asia Pacific Therapeutic Vaccines Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 126 Pages
SKU # TIP20577432

Description

The Asia Pacific therapeutic vaccines market is projected to grow significantly, reaching approximately US$ 85,862.88 thousand by 2031, up from US$ 34,213.87 thousand in 2024, with an estimated compound annual growth rate (CAGR) of 14.0% from 2024 to 2031.

Executive Summary and Market Analysis

The therapeutic vaccine market in the Asia Pacific region is witnessing robust growth, primarily fueled by advancements in technology and increased funding for vaccine research. Key players in this growth include China and India, which benefit from large populations, extensive immunization programs, and rising healthcare expenditures. Japan's advanced healthcare system and high vaccination rates also contribute significantly to market expansion. Furthermore, Australia is enhancing its market presence through strong government support and heightened public awareness regarding vaccination benefits.

Despite this growth, the market faces challenges such as stringent regulatory frameworks, high production and development costs, and limited awareness among patients and healthcare professionals. Addressing these challenges is crucial for the continued growth of the therapeutic vaccine sector in the Asia Pacific.

Market Segmentation Analysis

The therapeutic vaccines market can be segmented by product type, technology, and end user:

By Product: The market is divided into cancer vaccines, infectious disease vaccines, and others, with cancer vaccines holding the largest market share in 2024.
By Technology: The market is categorized into allogenic and autologous vaccines, with allogenic vaccines leading in market share in 2024.
By End User: The end users include hospitals, clinics, and others, with hospitals accounting for the largest share in 2024.

Market Outlook

The demand for innovative treatment options is driving significant investments and advancements in the therapeutic vaccines sector. The increasing number of clinical candidates progressing through various development stages is indicative of this trend. Innovative research and development in biotechnology are producing advanced therapeutic vaccines targeting a range of diseases, including chronic conditions like cancer and newer infections. For instance, Moderna's mRNA-4157 is currently in phase 2 trials, showing promise in combination with checkpoint inhibitors for melanoma treatment. The therapeutic vaccine pipeline is also expanding to address autoimmune diseases and infectious diseases such as HIV, HPV, and HBV.

Several companies are focusing on scientific and technical excellence to develop and launch new therapeutic vaccines. The expanding pipeline of vaccine candidates targeting diverse diseases presents significant opportunities to meet unmet medical needs. Below is a summary of notable therapeutic vaccine candidates:

ADXS11–001: A bacterial vector vaccine in Phase I/II for cervical carcinoma.
ISA101: A peptide/protein vaccine in Phase II for solid tumors.
NeoVax: A personalized peptide vaccine in Phase I for kidney cancer.
mRNA-4157: An mRNA-based neoantigen vaccine in Phase I/II for melanoma.
VGX-3100: A DNA vaccine in Phase I/II for cervical and head and neck cancers.
NASVAC: A virus-like particle vaccine in Phase III for HBV infection.
iHIVARNA: An mRNA vaccine in Phase I for HIV infection.

The ongoing clinical trials indicate a promising future for the therapeutic vaccines market, with new treatment options emerging to address unmet medical needs.

Country Insights

The Asia Pacific therapeutic vaccines market includes countries such as China, Japan, India, Australia, South Korea, and others. Australia is expected to maintain the largest market share in 2024, driven by its strong healthcare infrastructure and active involvement in vaccine development. Notably, Australian researchers have made significant progress in developing a therapeutic vaccine for Epstein-Barr virus (EBV), which could revolutionize treatment for diseases associated with EBV, including multiple sclerosis and certain cancers.

Additionally, South Australia is establishing itself as a leader in mRNA technology with the development of a state-of-the-art mRNA production facility, BioCina. This facility aims to enhance the production of therapeutic drugs and vaccines, supported by US$ 10 million in funding from the Australian government.

Company Profiles

Key players in the therapeutic vaccines market include CureVac SE, THERAVECTYS SA, Transgene SA, INOVIO Pharmaceuticals Inc, ISA Pharmaceuticals BV, Amgen Inc, Merck & Co Inc, Serum Institute of India Pvt. Ltd, BioNTech SE, and Dendreon. These companies are pursuing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative products.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Therapeutics Vaccine Market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Therapeutics Vaccine Market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific Therapeutics vaccine Market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

126 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic Conditions
4.1.2 Increasing Investments and Funding for Vaccine Development
4.2 Market Restraints
4.2.1 Regulatory Challenges
4.3 Market Opportunities
4.3.1 Extending Product Pipeline
4.4 Future Trends
4.4.1 Advancements in Vaccine Technology
4.5 Impact of Drivers and Restraints:
5. Therapeutic Vaccines Market - Asia Pacific Market Analysis
5.1 Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
5.2 Asia Pacific Therapeutic Vaccines Market Forecast Analysis
6. Asia Pacific Therapeutic Vaccines Market Analysis - by Product
6.1 Cancer Vaccine
6.1.1 Overview
6.1.2 Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.2 infectious Disease Vaccine
6.2.1 Overview
6.2.2 infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
6.3 Others
6.3.1 Overview
6.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7. Asia Pacific Therapeutic Vaccines Market Analysis - by Technology
7.1 Allogenic Vaccine
7.1.1 Overview
7.1.2 Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
7.2 Autologous Vaccine
7.2.1 Overview
7.2.2 Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8. Asia Pacific Therapeutic Vaccines Market Analysis - by End User
8.1 Hospitals
8.1.1 Overview
8.1.2 Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.2 Clinics
8.2.1 Overview
8.2.2 Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
8.3 Others
8.3.1 Overview
8.3.2 Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9. Asia Pacific Therapeutic Vaccines Market - Country Analysis
9.1 Asia Pacific
9.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.1 Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
9.1.1.2 China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.2.1 China: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.2.2 China: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.2.3 China: Asia Pacific Therapeutic Vaccines Market Share - by End User
9.1.1.3 Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.3.1 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.3.2 Japan: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.3.3 Japan: Asia Pacific Therapeutic Vaccines Market Share - by End User
9.1.1.4 India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.4.1 India: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.4.2 India: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.4.3 India: Asia Pacific Therapeutic Vaccines Market Share - by End User
9.1.1.5 South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.5.1 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.5.2 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.5.3 South Korea: Asia Pacific Therapeutic Vaccines Market Share - by End User
9.1.1.6 Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.6.1 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.6.2 Australia: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.6.3 Australia: Asia Pacific Therapeutic Vaccines Market Share - by End User
9.1.1.7 Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
9.1.1.7.1 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Product
9.1.1.7.2 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by Technology
9.1.1.7.3 Rest of APAC: Asia Pacific Therapeutic Vaccines Market Share - by End User
10. Therapeutic Vaccines Market - Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Therapeutic Vaccines Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Dendreon
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 BioNTech SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Serum Institute of India Pvt. Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Merck & Co Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Amgen Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 ISA Pharmaceuticals BV
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 INOVIO Pharmaceuticals Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Transgene SA
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 THERAVECTYS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 CureVac SE
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms
List of Tables
Table 1. Asia Pacific Therapeutic Vaccines Market Segmentation
Table 2. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Table 3. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Product
Table 4. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Technology
Table 5. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
Table 6. Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
Table 7. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 8. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 9. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 10. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 11. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 12. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 13. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 14. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 15. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 16. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 17. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 18. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 19. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 20. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Product
Table 23. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Technology
Table 24. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
Table 25. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
Table 26. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
Table 27. Glossary of Terms, Therapeutic Vaccines Market
 
List of Figures
Figure 1. Asia Pacific Therapeutic Vaccines Market Segmentation - Country
Figure 2. Asia Pacific Therapeutic Vaccines Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
Figure 5. Asia Pacific Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
Figure 6. Cancer Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 7. infectious Disease Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 8. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 9. Asia Pacific Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
Figure 10. Allogenic Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 11. Autologous Vaccine: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 12. Asia Pacific Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
Figure 13. Hospitals: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 14. Clinics: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 15. Others: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
Figure 16. Asia Pacific Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
Figure 17. China: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 18. Japan: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 19. India: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 20. South Korea: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 21. Australia: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 22. Rest of APAC: Asia Pacific Therapeutic Vaccines Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
Figure 23. Growth Strategies in the Therapeutic Vaccines Market

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us